Meningococcal tetravalent conjugate vaccine

Expert Opinion on Biological Therapy

Volumn 8, Issue 12, 2008, Pages 1941-1946

  Smith, Michael J ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Conjugate vaccines; Meningococcal disease

Indexed keywords

MCV 4; MENACRA; MENINGOCOCCUS VACCINE; MENUMUNE; MPSV 4; UNCLASSIFIED DRUG; VACCINE;

ALLERGY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; GUILLAIN BARRE SYNDROME; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION RISK; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MENINGOCOCCOSIS; NONHUMAN; POSTMARKETING SURVEILLANCE; REVIEW; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ADULT; CLINICAL TRIALS AS TOPIC; GUILLAIN-BARRE SYNDROME; HUMANS; MENINGOCOCCAL VACCINES; PRODUCT SURVEILLANCE, POSTMARKETING;

NEISSERIA MENINGITIDIS;

EID: 57649235896     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802538455     Document Type: Review

References (31)

1. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2005;54(RR-7):1-21
2. Center for Diseases Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis,2007. [cited 2008 October 6]; Available from: http://www.cdc.gov/ncidod/dbmd/abcs/survreports/mening07.pdf
3. Rosenstein NE, Perkins BA, Stephens DS, et al. Medical progress: Meningococcal disease. N Engl J Med 2001;344(18):1378-88
4. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969;129(6):1307-26
5. Campbell JD, Edelman R, King JC, et al. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. J Infect Dis 2002;186(12):1848-51
6. Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001;69(3):1568-73
7. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003;10(5):780-6
8. Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005;159(10):907-13
9. Food and Drug Administration. Product approval information-licensing action. [cited 2008 June 5]; Available from: http://www.fda.gov/cber/ products/menactra.htm
10. Pichichero M, Casey J, Blatter M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharicle vaccine in two- to ten-year-old children. Pediatr Infect Dis J 2005;24(1):57-62
11. Update: Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine - United States, June 2005-September 2006. Morb Mortal Wkly Rep 2006;55(41):1120-4
12. Vu DM, Welsch JA, Zuno-Mitchell P, et al. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis 2006;193(6):821-8
13. Pichichero M, Papa T, Blatter M, et al. Immune memory in children previously vaccinated with an experimental quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 2006;25(11):995-1000
14. National vaccination coverage among adolescents aged 13-17 years - United States, 2006. Morb Mortal Wkly Rep 2007;56(34):885-8
15. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348(18):1737-46
16. Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children - United States, 1998-2000. Morb Mortal Wkly Rep 2002;51(11):234-7
17. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004;364(9431):365-7
18. Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001;357(9251):195-6
19. Ramsay ME, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. Br Med J 2003;326(7385):365-6
20. Maiden MCJ, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002;359(9320):1829-30
21. Maiden MCJ, Ibarz-Pavon AR, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008;197(5):737-43
22. Ortega-Sanchez IR, Meltzer MI, Shepard C, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis 2008;46(1):1-13
23. Report from the Advisory Committee on Immunization Practices (ACIP): decision not to recommend routine vaccination of all children aged 2-10 years with quadrivalent meningococcal conjugate vaccine (MCV4). Morb Mortal Wkly Rep 2008;57(17):462-5
24. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis - implications for vaccine development and pathogenesis. Lancet 1983;2(8346):355-7
25. Tondella MLC, Popovic T, Rosenstein NE, et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. J Clin Microbiol 2000;38(9):3323-8
26. Kelly C, Arnold R, Galloway Y, O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007;166(7):817-23
27. Holst J. Strategies for development of universal vaccines against meningococcal serogroup B disease. Hum Vaccin 2007;3(6):290-4
28. Rennels M, King J, Ryall R, et al. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004;23(5):429-35
29. Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants - a randomized controlled trial. JAMA 2008;299(2):173-84
30. Snape MD, Kelly DF, Lewis S, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. Br Med J 2008;336(7659):1487
31. de Roux A, Schmoele-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: Conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008;46(7):1015-23